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Abstract
Introduction: Chronic venous diseases (CVD), because of its chronic and progressive nature, impairs patients' quality 
of life (Qol).
Aim: To compare the OoL in patients with primary superficial venous insufficiency at different stages before and 
after compression therapy (CT).
Material and methods: We compared the change in the QoL parameters from baseline to the end of a 6-month 
compression therapy. 180 subjects were enrolled. They were subdivided into 6 equal subgroups according to CEAP 
classes. The OoL was assessed using questionnaires, the generał SF-36v2 and the disease-specific CIVIQ-20. At the 
beginning and after the completion of the study intervention, the severity of CVD was assessed in each patient 
using CEAP and VCSS. The pain intensity was assessed using the numerical rating scale.
Results: The CT reduced the severity of CVD, which translated into the increased size of C2 an d C5 subgroups, and 
reduced size of C3 and C6 subgroups. Another marker of reduced severity of CVD after CT was a significant reduc- 
tion in VCSS scores in Cl, and C3-C6 subgroups. A 6-month CT was associated with a significant OoL improvement 
in all CEAP class-based subgroups, across all individual and composite domains of SF-36v2, as well as dimensions 
and GIS of CIVIQ-20. Similarly, there was a significant pain reduction reported in all CEAP class-based subgroups. 
Conclusions: Compression therapy using ready-made compression hosiery significantly affects the quality of life 
in patients with chronic venous disease at all its stages, CEAP classes C1-C6.
Key words: compression therapy, chronic venous diseases, quality of life.
Introduction
According to the WHO, health is not merely the ab- 
sence of disease or infirmity, but a state of complete 
physical, mental and social well-being. It, therefore, as- 
sumes maintenance of well-being and satisfactory func- 
tion across all aspects of life [1, 2]. Each curative treat- 
ment aims at returning to complete health. In patients 
with chronic diseases, the ability to maintain highest
achievable quality of life (QoL) is an additional marker of 
treatment success [1]. WHO defines the OoL as “the indi- 
vidual’s perception of their position in life in the context 
of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and con- 
cerns”. It is affected by a number of interrelated factors, 
including but not limited to physical health, interpersonal 
relationships and environmental attributes which an in- 
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dividual considers important [3]. OoL affects all domains 
of life crucial for an individual’s existence. Discussed 
in the context of health and disease, the QoL is usu- 
ally termed health-related quality of life (HRQoL) [3, 4]. 
The OoL is assessed using different questionnaire mea­
sures, both generał and disease-specific.
CVD affects 30-50% of adult population and its chron­
ic, progressive naturę significantly impairs the quality of 
life [5, 6]. The higher severity of CVD, expressed as CEAP 
class, the worse the HRQoL [7]. The QoL is assessed in pa- 
tients with CVD using different questionnaire measures, 
both generał and disease-specific [3, 7]. The 36-item Short 
Form Health survey (SF-36) is a recommended general 
OoL measure. The CVD-specific validated OoL measures 
include Chronić Venous Insufficiency OoL Ouestionnaire 
(CMO-20), Venous Insufficiency Epidemiological and Eco- 
nomic Study (VEINES-QoL), and Aberdeen Varicose Vein 
Questionnaire (AVVQ) [8, 9].
Compression therapy (CT) is an established treatment 
of CVD with a plethora of clinical studies supporting its 
efficacy [10,11]. However, the number of papers evaluat- 
ing the changes in quality of life after using CT is rela- 
tively low.
Aim
The aim of the study was to assess the quality of life 
in patients with primary superficial venous insufficiency 
at different stages (CEAP classes) after CT. Superficial ve- 
nous insufficiency is considered a primary condition, as 
it is of undetermined origin, established genetic links and 
lifestyle-related [12].
Material and methods
The study protocol was approved by the Bioethical 
Committee of the Medical University of Silesia in Kato­
wice (approval no. KNW/0022/KB/103/16).
The study was carried out at the Department of In- 
ternal Diseases, Angiology and Physical Medicine in By­
tom, Medical University of Silesia in Katowice, as well 
as Vascular Clinic in Koszęcin. One hundred and eighty 
subjects with CVD due to primary superficial venous in­
sufficiency, previously untreated with CT, were enrolled in 
the survey-based study. The sample was divided evenly, 
into subgroups based on the CVD severity assessed 
using CEAP classification (Cl to C6, 30 subjects each). 
The exclusion criteria were chronic comorbidities likely to 
affect the OoL, such as malignancies, severe chronic ob- 
structive pulmonary disease (COPD), respiratory failure, 
severe heart failure, rheumatoid arthritis, any locomo- 
tor system pathology making the patient non-ambulant, 
with associated chronic leg pain, mental health problems 
making the patient uncooperative, as well as pregnancy 
and postpartum. Furthermore, the patients with a history 
of deep vein thrombosis (DVT) and those with a history 
of invasive treatment of CVD within 2 years prior to en- 
rolment, were excluded. Patients after changes to CVD 
treatment made throughout the study were excluded, 
just as those non-compliant with their prescribed CT 
regimen, preferring bandage-only CT and those who, 
due to leg deformity or size, posed a significant challenge 
selecting and fitting appropriate compression hosiery 
products. Finally, the presence of contraindications to CT 
was an exclusion criterion. During the first visit/assess- 
ment, ready-made compression hosiery was prescribed 
(stockings, tights, knee-high socks), with the compres- 
sion level selected individually based on the international 
guidelines [10, 11, 13-15]. Each patient was educated on 
the need to wear their prescribed compression prod- 
ucts daily for not less than 8 h/day. The compression 
hosiery was always removed for the night. In patients 
with VLUs, ready-made 2-in-1 compression systems, with 
a liner worn for 24 h, were used. During the first visit, the 
consultant angiologist assessed the severity of CVD ac- 
cording to the Clinical-Etiology-Anatomy-Pathophysiology 
(CEAP) class and Venous Clinical Severity Score (VCSS). 
The CEAP classification is intended to grade CVD severity 
based on current clinical presentation [16]. VCSS, on the 
other hand, enables a longitudinal comparison of CVD 
symptom severity in a group receiving specific treat- 
ment and is recommended as a preferred measure in 
clinical research [16]. Lower extremity Doppler scan was 
performed in all patients using Logiq 5 and Logiq 7 scan- 
ners. The ankle-brachial index (ABI) and the body mass 
index (BMI) were calculated for each enrolled patient. It 
was followed by a survey, which ascertained social and 
demographic characteristics of the patients, alongside 
their CVD risk factors and pain severity assessed using 
the Numerical Rating Scale (NRS). The NRS is a horizon- 
tal, linear scale ranging from 0, which corresponds to 
no pain, to 10, which corresponds to the most severe 
imaginable pain ever. It is a validated, reliable measure 
[17]. Each subject was requested to complete two Quality 
of Life measures. The first, generał, non-disease-specific 
questionnaire was the Medical Outcomes Study 36-Items 
Short-Form Health Survey version 2 (SF-36v2) consisting 
of 36 items across 11 categories, which correspond to 
8 quality of life domains, including Physical Functioning 
(PF), Role Physical (RP), Bodily Pain (BP), General Health 
(GH), Vitality (VT), Social Functioning (SF), Role Emotion- 
al (RE), and Mental Health (MH). Two composite scores 
were computed, the Physical Health Summary (PHS) and 
the Mental Health Summary (MHS) scores. The PHS was 
computed as a mean of the PF, RP, BP and GH scores. 
The MHC was computed as a mean of the VT, SF, RE and 
MH scores [3]. The higher the score in each domain, the 
better the quality of life. The Polish language version of 
the questionnaire was made available for use based on 
license no. SLAQM035217-CT177581-OP052675. Another 
questionnaire was a validated, Polish version of CVD-spe- 
cifie CMO-20 authored by professor Launois, the transla- 
390 Advances in Dermatology and Allergology 3, June/2021
The effect of compression therapy on qoality of life in patients with chronic venoos disease: a comparative 6-month stody
tion and validation of which was supported by a research 
grant from Servier. The measure consists of 20 items 
pertaining to 4 QoL dimensions, namely: pain dimension 
(4 items), physical dimension (4 items), social dimen- 
sion (3 items) and a psychological dimension (9 items). 
The dimension scores are calculated as a total of rele- 
vant item scores. The total score, known as the Global 
Index Score (GIS) is computed using the formula [8, 18]. 
The lower the score in each domain and GIS, the better 
the quality of life. The measure was originally intended 
for CEAP classes C2-C5 and is used in particular in CEAP 
C2 patients [19]. With time, CEAP C0 and C1 patients were 
also assessed using CIVIQ-20. Due to item content and 
design, it is not intended for CEAP C6 patients, i.e. those 
with active VLUs [20]. There are, however, studies which 
report administrating validated translations of CIVIQ-20 
to C6 patients in an attempt to assess their QoL [21, 22].
After 6 months of CT, all patients were invited to a fol- 
low-up visit, during which they were clinically re-assessed 
(CEAP, VCSS). Also, the survey as described above was 
repeated, excluding the items pertaining to socio-demo- 
graphic characteristics and CVD risk factors, as these had 
been ascertained before.
Statistical analysis
The questionnaire data were checked for complete- 
ness, entered into the database and analysed statistically 
usingthe Statistica bundle. The between-gronp differenc- 
es were determined using the T-test or Mann-Whitney 
U-test. The paired T-test and Wilcoxon signed-rank test 
were used for parametric and non-parametric quantita- 
tive variables, respectively. For qualitative variables, the 
%2 and the maximum likelihood estimation (MLE) were 
used. The p < 0.05 was considered significant for all com- 
parisons.
Results
The demographic and social characteristics of the 
study group are shown in Table 1. The mean patient-re- 
ported CT wear time was 9.33 ±1.42, 9.3 ±1.5, 9.66 ±1.7, 
10.2 ±1.5, 9.7 ±1.7, and 10.4 ±1.6 h in CEAP classes C1 to 
C6, respectively. At the end of the study, changes in CEAP 
class-based subgroup sizes were noticed. The C2 group 
grew from 30 to 49 subjects, whereas the C3 group de- 
creased in size from 30 to 11 subjects. Similarly, the C5 
group grew from 30 to 52 at the expense of the C6 group 
size reduction from 30 to only 8. The decreased size of the 
C6 subgroup was associated with a complete resolution 
of venous leg ulcerations in 22 subjects. After 6 months, 
there was a significant rednction in CVD severity assessed 
using VCSS in all CEAP class-based subgroups except for 
C2 (Figure 1).
Figure 1. The mean (± SD) Venous Clinical Severity Score 
(VCSS) at two time - points (VCSS1) baseline and after the 
end of CT (VCSS2) in individual CEAP class-based patient 
groups with a statistical difference analysis (*p < 0.05, 
***p < 0.0001)
Table 1. Demographic and social characteristics of the study sample by CEAP class

















1 29/1 35.40 25.53 24/6 30/0 7/23 30/0
(96.67/3.33) (±4.16) (±1.70) (80/20) (100/0) (23/33) (100/0)
2 25/5 45.40 26.85 20/10 27/3 4/26 30/0
(83.33/16.67) (±10.25) (±1.50) (66.67/33.33) (90/10) (13.33/86.67) (100/0)
3 24/6 47.96 27.60 15/15 25/5 4/26 30/0
(80.0/20.0) (±7.29) (±2.76) (50/50) (83.33/16.67) (13.33/86.67) (100/0)
4 14/16 54.00 28.75 17/13 18/12 7/23 30/0
(46.67/53.33) (±7.24) (±2.30) (56.67/43.33) (60/40) (23.33/76.67) (100/0)
5 17/13 58.4 29.52 20/10 12/18 5/25 28/2
(56.67/43.33) (±6.39) (±2.89) (66.67/33.33) (40/60) (16.67/83.33) (93.33/6.67)
6 19/11 58.53 30.38 19/11 10/20 6/24 28/2
(63.33/36.67) (±10.86) (±3.54) (63.33/36.67) (33.33/66.66) (20/80) (93.33/6.67)
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Table 2. The mean (± SD) QoL scores in SF-36v2 at baseline and after 6 months of CT
CEAP Domains
Class PF RP BP GH VT SF RE MH
before/after before/after before/after before/after before/after before/after before/after before/after
P-value P-value P-value P-value P-value P-value P-value P-value
1 76.33 (±12.8)/ 64.16 (±13.2)/ 48.2 (±16.72)/ 29.13 (±24.3)/ 40.62 (±16.55)/ 49.16 (±22.7)/ 70.83 (±13.79)/ 46.66 (±16.6)/
98.66 (±2.9) 98.54 (±4.2) 98.93 (±4.0) 88.46 (±12.9) 82.91 (±9.27) 98.75 (±3.8) 99.44 (±2.1) 87.16 (±5.9)
< 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
2 72.66 (±16.33)/ 53.53 (±15.28)/ 44.06 (±20.49)/ 25.73 (±17.19)/ 42.08 (±15.9)/ 46.66 (±24.1)/ 57.5 (±15.05)/ 46.33 (±16.23)/
97.66 (±4.68) 98.54 (±4.24) 96.4 (±7.6) 88.13 (±9.67) 80.62 (±10.03) 97.5 (±6.88) 98.88 (±3.61) 85.5 (±8.44)
< 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
3 63.16 (±15.7)/ 48.33 (±12.9)/ 33.43 (±14.5)/ 12.23 (±11.93)/ 29.37 (±11.38)/ 35.83 (±21.95)/ 50.55 (±15.46)/ 35.83 (±9.12)/
95.83 (±4.56) 95.62 (±7.36) 91.8 (±10.66) 85.93 (±9.75) 76.45 (±8.15) 96.25 (±6.68) 94.16 (±10.06) 83.66 (±6.81)
< 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
4 55.83 (±17.66)/ 39.16 (±18.04)/ 22.56 (±12.95)/ 13.33 (±14.81)/ 20.41 (±13.12)/ 31.25 (±21.46)/ 44.72 (±19.01)/ 26.5 (±13.2)/
89.66 (±6.68) 89.79 (±13.68) 83.26 (±9.37) 79.1 (±11.13) 71.87 (±6.71) 92.08 (±10.62) 90.83 (±11.65) 81.16 (±6.25)
< 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
47.00 (±12.29)/ 26.66 (±13.12)/ 14.00 (±14.47)/ 6.16 (±10.05)/ 15.83 (±14.47)/ 17.91 (±12.57)/ 30.27 (±17.84)/ 22.0 (±16.1)/
5 85.33 (±7.87) 81.45 (±14.99) 73.53 (±11.85) 75.53 (±10.94) 70.62 (±7.18) 82.5 (±12.1) 84.16 (±13.72) 80.0 (±7.54)
< 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
21.33 (±17.36)/ 10.62 (±13.24)/ 0.00 (±0.00)/ 1.00 (±3.8)/ 7.29 (±9.99)/ 0.41 (±2.28)/ 14.16 (±15.18)/ 9.5 (±10.2)/
6 78.99 (±12.82) 81.25 (±19.14) 66.56 (±13.26) 66.43 (±13.99) 64.68 (±10.8) 72.91 (±15.77) 82.22 (±18.66) 73.9 (±9.61)
< 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
CEAP - Clinical, Etiological, Anatomical and Pathophysiological grade, SF-36v2 domains: PF - Physical Functioning, RP - Role Physical, BP - Bodily Pain, 
CH-Cenerat Health, VT- Vitality, RE-Role Emotional, MH-Mental Health, p-statistical signiflcance.
There was a significant reduction in pain severity 
assessed using NRS in all CEAP class-based subgroups 
(Figure 2).
There was a significant change of SF-36v2 scores 
reflecting the improved QoL across all individual and 
composite domains. The improvement was seen in all 
CEAP class-based subgroups. The largest improvement 
was noted in the CEAP C6 subgroup, where the scores 
increased the most in all individual domains (except for 
GH) and collective scores (Table 2, Figure 3).
The re-assessment with CIVIQ-20 after 6 months CT 
demonstrated a significant improvement in qnality of life
□ NRS1 □ NRS2
Figure 2. The mean (± SD) numeric rating scale scores at 
two time-points: baseline (NRS1) and after the end of CT 
(NRS2) by CEAP class, with a statistical difference analysis 
(***p < 0.0001)
Figure 3. A comparison of means (± SD) for the SF-36v2 do- 
mains: Mental Health Summary (MHS) and Physical Health 
Summary (PHS) at two time-points: (1) baseline, and (2) af- 
ter the end of CT, by CEAP class, with a statistical difference 
analysis (***p < 0.0001)
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P-value P-value P-value P-value
1 11.8 (±2.92)/4.16 (±0.37) 8.43 (±2.51)/4.0 (±0.00) 5.9 (±2.18)/3.03 (±0.18) 19.53 (±6.75)/10.1 (±0.8)
< 0.0001 < 0.0001 < 0.0001 < 0.0001
2 12.4 (±3.74)/4.96 (±1.21) 9.83 (±3.48)/4.3 (±0.7) 6.36 (±3.28)/3.16 (±0.53) 20.86 (±8.08)/11.1 (±1.6)
< 0.0001 < 0.0001 < 0.0001 < 0.0001
3 14.33 (±2.91)/5.6 (±1.45) 11.66 (±2.92)/4.8 (±1.12) 7.6 (±3.26)/3.3 (±0.59) 25.93 (±8.25)/11.0 (±1.17)
< 0.0001 < 0.0001 < 0.0001 < 0.0001
4 16.6 (±3.2)/6.7 (±1.23) 13.53 (±3.33)/5.73 (±1.48) 8.9 (±3.35)/3.76 (±0.85) 28.2 (±8.5)/12.23 (±1.25)
< 0.0001 < 0.0001 < 0.0001 < 0.0001
5 18.06 (±2.61)/8.43 (±2.22) 15.2 (±2.24)/3.36 (±12.49) 10.8 (±2.1)/4.56 (±1.79) 32.86 (±6.44)/14.0 (±2.31)
< 0.0001 < 0.0001 < 0.0001 < 0.0001
6 19.73 (±0.69)/8.6 (±1.61) 17.3 (±1.7)/7.83 (±2.18) 13.63 (±1.06)/5.66 (±1.88) 40.33 (±4.16)/15.9 (±3.36)
< 0.0001 < 0.0001 < 0.0001 < 0.0001
CEAP-CUnical, EEtological, Anatomical and Pathophysiological grade, CMO-20 dimensions: pain dimension, physical dimension, social dimension, and psy- 
chological dimension, p - statisticai significance.
across all four basic QoL domains and in GIS, in all CEAP 
class-based subgroups (Table 3, Figure 4).
There was no treatment-related adverse event re- 
ported during the compression therapy.
Discussion
The QoL assessment in patients with CVD demon- 
strated a significant disease-related impairment in OoL, 
which worsens gradually with disease progression [23, 
24]. The lowest QoL is observed in patients with CVD 
CEAP class C6. Whereas the number of papers to assess 
QoL in patients with CVD after treatment is limited, there 
is evidence that CVD treatment positively affects QoL 
[19, 25]. The majority of research papers focus on assess- 
ing the efficacy of medical and invasive CVD treatments 
with only few evaluating the QoL after CT, in chosen, 
usually higher CEAP classes. Our study assessed QoL 
in patients at all stages of CVD, CEAP classes C1 to C6, 
with a follow-up period of 6 months, longer than other 
comparable studies. The subjects were evaluated for any 
changes to their clinical presentation and quality of life.
CT reduces intraluminal venous pressure, counter- 
acts the gravity, improves venons outflow and rednces 
venous stasis thereby slowing clinical progression or 
actually improving the symptoms of CVD. In our study, 
we demonstrated a reduction in severity of clinical CVD 
symptoms after 6 months of CT. It was reflected in a nu- 
merical shift within CEAP class-based subgroup sizes 
and a change in VCSS scores. The size of C2 and C5 sub- 
groups increased, which was related to reduced oedema,
■ GISl E1GIS2
Figure 4. The mean (± SD) global index score (GIS) of CMO-20 
at two time-points: (1) baseline, and (2) after the end of CT, 
with a statisticai difference analysis [***p < 0.0001)
skin lesions of healing of venous leg ulcers (VLUs). The 
VCSS assessment confirmed severity rednction of clini- 
cal CVD symptoms in all CEAP class-based subgroups. 
In classes C1, and C3 to C6, the VCSS score change was 
significant. The non-significant change in class C2 can 
be explained by the specificity of the VCSS scalę, where 
additional points are awarded for using CT. Regular 
nse of CT gives additional 3 points, which significantly 
changes the total score, especially in the lowest CEAP 
class-based subgroups [26]. The key clinical symptoms 
affecting changes in OoL are pain and oedema [22, 27]. 
Pain is the main complaint reported by patients with CVD 
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which makes them seek medical advice [21]. It occurs at 
any stage of CVD and increases in incidence and sever- 
ity with disease progression. Pain is reported by 64-82% 
of patients with VLUs [28]. Pain limits physical activity 
and secondarily reduces employability, worsening patient 
social isolation and dependence. It also affects patient 
mental health, decreasing their self-esteem. Chronic pain 
causes anxiety, helplessness, and resignation with lack 
oftrust in treatment efficacy [23]. Nocturnal pains in pa- 
tients with VLUs deprive them of sleep causing insomnia 
and exhaustion [29]. It was confirmed that appropriately 
selected and fitted compression therapy, reduces pain 
in approximately 90% of patients with chronic venous 
insufficiency (CVI) [30]. In our study, the numeric rating 
scale confirmed a significant pain reduction after CT. 
It was observed in each CEAP class subgroup. The highest 
pain reduction was observed in the C6 subgroup.
The main aim of the study was to assess the QoL af- 
ter using CT. The QoL is impaired in patients with CVD 
across all measurable domains. The magnitude of im- 
pairment differs between domains, depending on se- 
verity of CVD. For example, patients with varicose veins 
experience impairment in physical rather than mental 
QoL domains [31]. In patients with VLUs, the QoL impair- 
ment increases gradually, which is reflected in worsening 
physical (RP, PF, BP, GH) and mental (SR, RE) scores [24]. 
The largest CVD-related QoL deterioration is seen in the 
pain domain [21, 32].
In 2005, Andreozzi et al. evaluated the effect of 
4-month CT on QoL in patients with CVI (only CEAP 
classes C2 to C5 were studied) and demonstrated a sig- 
nificant improvement across all domains in C3-C5 CEAP 
class-based subgroups. In the C2 class, however, whereas 
some improvement was demonstrated across all SF-36v2 
domains, it was non-significant in the PF, GH and MH 
domains and significant in the remaining domains [19]. 
This was explained by the absence of quality of life im- 
pairment across the areas represented by these domains 
at baseline, as well as the small sample size [19]. In our 
study, there was a significant score improvement across 
all domains of the SF-36v2 in all enrolled CEAP classes, 
i.e. C1-C6. It should be noted that the size of the C2 sub- 
group was similar to that of Andreozzi et al. (30 vs. 27). 
The difference in findings can, therefore, be explained 
by our longer follow-up period or patient-declared 100% 
compliance with CT recommendations.
After 6 months of the study, the highest score im- 
provements were observed in the GH and BP domains, 
which represent general health and bodily pain. The larg- 
est QoL improvement across all basic domains (PF, RP, BP, 
VT, SF, RE and MH) and both composite domains (PHS, 
MHS) of the SF-36v2 was observed in subjects classed 
as CEAP C6 at baseline. It should be noted that these pa- 
tients had the lowest baseline QoL.
The assessment using the CVD-specific measure, 
CMO-20, also confirmed improved OoL in all CEAP class- 
based subgroups. Significant score changes were noted 
across all four basic dimensions as well as GIS. Just as it 
was the case with SF-36v2 scores, the higher the CEAP 
class, the larger QoL improvement was observed. The en- 
rolment of patients representing all CEAP classes, C1-C6, 
was only possible due to the availability of ready-made 
2-in-1 compression systems for patients with VLUs, that 
is, the CEAP C6 class. These systems have liners which 
significantly facilitate patienfis daily activities and virtu- 
ally replace bandages. To date, there has been no com- 
parative study to evaluate changes in QoL in patients 
with CVD after CT using CIVIQ-20.
A prerequisite study completion in our sample was 
their full compliance with CT recommendations. Meet- 
ing this condition can often be an obstacle. According 
to Raiu et al., up to 63% of patients with CVD do not 
use CT. The numbers are similar in both sexes across all 
CEAP classes and are attributable to the impossibility to 
use CT, its lack of efficacy or non-adherence to treatment 
recommendations. In 1/3 of cases, non-adherence leads 
to the perceived lack of efficacy [33]. Non-adherence may 
be associated with perceived discomfort due to excessive 
skin dryness, itching, pressure or overheating sensation 
as well as difficulties puttingon compression hosiery. It is 
also associated with lack of understanding how CT works 
and patienfis level of education. For example, almost 
82% of patients with primary education refuse to use CT 
[30, 33, 34]. However, the reasons for the lack of CT use 
or its misuse are not solely attributable to patients. Phy- 
sicians, who fail to prescribe CT or insufficiently educate 
their patients on CT principles, are also partly to blame, 
which is reflected in survey-based studies [33]. There- 
fore, in our study, particular care was taken to educate 
the participants thoroughly on how CT works and how 
it should be used during the first visit. The study group 
consisted only of those who reported 100% adherence 
to CT recommendations over the 6-month period. This 
was crucial as only proper use of CT can reduce clinical 
symptoms and improve the quality of life in patients with 
CVD, which we have hopefully demonstrated. Perhaps 
our results will translate into more common use of this 
valuable treatment modality. Our study should encourage 
the use of CT in patients with CVD at all stages.
Conclusions
Compression therapy using ready-made compres- 
sion hosiery significantly affects the quality of life in pa- 
tients with chronic venous disease at all its stages, CEAP 
classes C1-C6. There was a significant OoL improvement 
across all domains ascertained using the SF-36v2 and 
CIVIQ-20 measures. Alongside appropriate compression 
hosiery selection, treatment adherence, i.e. wearing the 
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compression product for long enough during a day, is 
a prerequisite for CT efficacy. Patient education on princi- 
ples and detailed recommendations for using CT can help 
to ensure the optimum clinical effect and improved OoL.
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